RU2014146031A - Pharmaceutical gel based on doxorubicin and organosilicon niosomes-niosomes for the treatment of skin cancer - Google Patents

Pharmaceutical gel based on doxorubicin and organosilicon niosomes-niosomes for the treatment of skin cancer Download PDF

Info

Publication number
RU2014146031A
RU2014146031A RU2014146031A RU2014146031A RU2014146031A RU 2014146031 A RU2014146031 A RU 2014146031A RU 2014146031 A RU2014146031 A RU 2014146031A RU 2014146031 A RU2014146031 A RU 2014146031A RU 2014146031 A RU2014146031 A RU 2014146031A
Authority
RU
Russia
Prior art keywords
niosomes
doxorubicin
organosilicon
treatment
skin cancer
Prior art date
Application number
RU2014146031A
Other languages
Russian (ru)
Other versions
RU2600164C2 (en
Inventor
Игорь Александрович Базиков
Original Assignee
Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии" filed Critical Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии"
Priority to RU2014146031/15A priority Critical patent/RU2600164C2/en
Publication of RU2014146031A publication Critical patent/RU2014146031A/en
Application granted granted Critical
Publication of RU2600164C2 publication Critical patent/RU2600164C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Трансдермальное средство, включающее противоопухолевый препарат доксорубицин, отличающееся тем, что доксорубицин в концентрации 5 мг/мл инкапсулирован в кремнийорганические ниосомы с 10%-ным содержанием в геле.A transdermal drug, including the antitumor drug doxorubicin, characterized in that doxorubicin at a concentration of 5 mg / ml is encapsulated in organosilicon niosomes with a 10% gel content.

Claims (1)

Трансдермальное средство, включающее противоопухолевый препарат доксорубицин, отличающееся тем, что доксорубицин в концентрации 5 мг/мл инкапсулирован в кремнийорганические ниосомы с 10%-ным содержанием в геле. A transdermal drug, including the antitumor drug doxorubicin, characterized in that doxorubicin at a concentration of 5 mg / ml is encapsulated in organosilicon niosomes with a 10% gel content.
RU2014146031/15A 2014-11-17 2014-11-17 Doxorubicin and organosilicon nanoparticles-niosomes- based pharmaceutical gel for skin cancer treating RU2600164C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2014146031/15A RU2600164C2 (en) 2014-11-17 2014-11-17 Doxorubicin and organosilicon nanoparticles-niosomes- based pharmaceutical gel for skin cancer treating

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2014146031/15A RU2600164C2 (en) 2014-11-17 2014-11-17 Doxorubicin and organosilicon nanoparticles-niosomes- based pharmaceutical gel for skin cancer treating

Publications (2)

Publication Number Publication Date
RU2014146031A true RU2014146031A (en) 2016-06-10
RU2600164C2 RU2600164C2 (en) 2016-10-20

Family

ID=56114800

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014146031/15A RU2600164C2 (en) 2014-11-17 2014-11-17 Doxorubicin and organosilicon nanoparticles-niosomes- based pharmaceutical gel for skin cancer treating

Country Status (1)

Country Link
RU (1) RU2600164C2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101214829B1 (en) * 2005-02-22 2012-12-24 다우 코닝 코포레이션 Polyoxyalkylene-alkyl functional siloxane resins and aqueous compositions thereof
JP2009528348A (en) * 2006-02-28 2009-08-06 ダウ・コーニング・コーポレイション Silicone vesicles containing active agents
RU2411935C1 (en) * 2009-08-25 2011-02-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт биомедицинской химии им. В.Н. Ореховича РАМН (ИБМХ РАМН) Pharmaceutical composition based on doxorubicine and phospholipid nanoparticles for treatment of oncologic diseases

Also Published As

Publication number Publication date
RU2600164C2 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
CY1120506T1 (en) THERAPEUTIC ACTIVE UNIONS AND METHODS OF USING THESE
EA201691023A1 (en) PEPTIDOMIMETIC CONNECTIONS AND THEIR CONJUGATES ANTIBODIES WITH MEDICINE
EA201691059A1 (en) PEPTIDOMYMETICS COMPOUNDS AND THEIR CONJUGATES CONTAINING ANTIBODY AND MEDICINE
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
EA201890530A1 (en) CONJUGATES ANTIBODIES TO DLL3 AND MEDICINES AND METHODS OF THEIR USE
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
EA201890272A1 (en) AXL-SPECIFIC CONJUGATES ANTIBODY AND MEDICINE FOR THE TREATMENT OF CANCER
EA201401028A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY
MX2023000796A (en) Pharmaceutical composition, methods for treating and uses thereof.
WO2015130554A3 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
EA201591925A1 (en) THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION
EA201892834A1 (en) COMBINED CHEMOTHERAPY
TR201910866T4 (en) Combined preparations for cancer treatment.
MX2018008645A (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives.
CY1119532T1 (en) (S) -PYRILDOL AND THE PHARMACEUTALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EA202190281A1 (en) DERIVATIVES 3 - ((HETERO-) ARYL) -8-AMINO-2-OXO-1,3-DIAZA-SPIRO [4,5] DECANE
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
WO2017181099A8 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
EA201792560A1 (en) NANOPARTICLES FOR APPLICATION AS A THERAPEUTIC VACCINE
MX2017009608A (en) Anti-cancer compounds.
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
IT201700088621A1 (en) Food supplements for use in the treatment of diseases associated with alterations of peripheral nerve trophism.
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20161129